Audax Biosciences
PrivateLast Round
Corporate Funding
Oct 27, 2026
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Audax Biosciences is a biotechnology company that develops targeted immunotherapies for oncology and autoimmune diseases using its proprietary immunology research platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Audax Biosciences Comparables
Compare Audax Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Asher Biotherapeutics | 85% | |
| Anaveon | 85% | |
| Nammi Therapeutics | 83% |
Audax Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Oct 27, 2026 | ||||
| Corporate Funding | Apr 21, 2020 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 27, 2026
Raised $285M with Astellas Pharma Inc. participating.
- Apr 21, 2020
Raised funding from Gilead Sciences and Kite Pharma.
Recent news
Latest coverage and updates
- partners_withOct 28, 2026
On Oct 28th '26, Audax Biosciences Pty Ltd and Astellas Pharma Inc partner under an exclusive option and license agreement for DAX-044, with Astellas Pharma Inc receiving an option for worldwide development, manufacturing and commercialization rights and Audax Biosciences Pty Ltd retaining an option to co-fund and co-promote the program in Australia and New Zealand.
- licenses_technologyOct 28, 2026
On Oct 28th '26, Astellas Pharma Inc obtains an exclusive option from Audax Biosciences Pty Ltd to license DAX-044 worldwide for development, manufacturing, and commercialization upon exercise; Audax Biosciences Pty Ltd retains options to co-fund and co-promote the candidate in Australia and New Zealand.
- receives_financingOct 28, 2026
Audax Biosciences Pty Ltd is due to receive $285M in upfront and potential future option exercise payments and continues developing DAX-044 toward a Phase 1 study expected to commence in 2027.
Audax Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Audax Biosciences's valuation, stock price, and market status.
Is Audax Biosciences a public or private company?
Audax Biosciences is a private company.
What is the current stock price of Audax Biosciences?
Audax Biosciences is a private company, so its shares have no public market price. Caplight tracks Audax Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Audax Biosciences worth (valuation)?
Valuation information for Audax Biosciences is not publicly available.
Can I buy Audax Biosciences stock?
Audax Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Audax Biosciences's last funding round?
Audax Biosciences's most recent funding round was Corporate Funding on October 27, 2026.
Who are the main investors in Audax Biosciences?
Investor information for Audax Biosciences is not publicly disclosed.
Will Audax Biosciences IPO soon?
No public IPO plans have been announced for Audax Biosciences.
How can I track Audax Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Audax Biosciences's shares on secondary markets.